Copyright
©The Author(s) 2021.
World J Hepatol. Oct 27, 2021; 13(10): 1428-1438
Published online Oct 27, 2021. doi: 10.4254/wjh.v13.i10.1428
Published online Oct 27, 2021. doi: 10.4254/wjh.v13.i10.1428
Table 1 Clinical and laboratory characteristics in Wilson’s disease children with acute liver failure and hemolytic anemia
| Parameter | All (n = 51) | ALF and hemolytic anemia | Other clinical forms | P value | |
| Females, n (%) | 26 (50.98) | 8 (100) | 18 (41.86) | 0.00252 | |
| Mean age (yr) | 12.36 ± 3.74 | 14.59 ± 2.21 | 11.59 ± 3.79 | 0.03598 | |
| ALT (IU/L) | 131.54 ± 119.69 | 87.38 ±154.07 | 142.24 ± 110. 04 | 0.24969 | |
| AST (IU/L) | 125.05 ± 88.73 | 78.62 ± 47.44 | 136.30 ± 93.16 | 0.09950 | |
| TB (mg/dL) | 5.41 ± 12.93 | 22.55 ± 21.95 | 0.99 ± 0.95 | 0.000002 | |
| DB (mg/dL) | 4.20 ± 11.56 | 18.84 ± 20.40 | 0.42 ± 0.51 | 0.000007 | |
| GGT (IU/L) | 83.54 ± 43.44 | 97.71 ± 57.14 | 80.44 ± 40.33 | 0.34731 | |
| WBC (mm3) | 8568 ± 7360 | 14838 ± 14185 | 6666 ± 1799 | 0.00415 | |
| Hb (g/dL) | 12.15 ±2.96 | 7.4 ± 2.39 | 13.51 ± 1.22 | 0.000000 | |
| PLT (mm3) | 253306 ±125421 | 164875 ± 74043 | 278571 ± 126455 | 0.02142 | |
| INR | 2.94 ± 6.37 | 7.53 ± 11.34 | 1.18 ± 0.27 | 0.01359 | |
| KF ring, n (%) | 9 (17.65) | 3 (37.50) | 6 (13.95) | 0.10868 | |
| Ceruloplasmin (mg/dL) | 9.81 ± 6.118 | 7.98 ± 5.77 | 10.11 ± 6.19 | 0.39976 | |
| Urinary copper (μg/24 h) | 648.94 ± 1093.90 | 2 236.33 ± 2 174.46 | 384.38 ± 455.04 | 0.000006 | |
| Outcome, n (%) | 0.00121 | ||||
| Survivors | 47 (92.16) | 5 (62.50) | 42 (97.67) | ||
| Transplanted | 2 (3.92) | 2 (25.00) | 0 | ||
| Deceased | 2 (3.92) | 1 (12.50) | 1 (2.33) | ||
Table 2 Variants of ATP7B gene in children with hemolytic anemia and acute liver failure
| Variants | Hemolytic Anemia + ALF (8 patients) | Other clinical forms (44 patients) | P value | |
| p.Trp939Cys (c.2817G>T) | 5 homozygotes | 6 (42.86%) | 4 (4.55%) | 0.0000 |
| p.Lys844Ter (c.2530A>T) | 1 homozygotes | 4 (28.57%) | 1 (1.14%) | 0.0000 |
| 3 heterozygotes | ||||
| p.Gly1341Asp (c.4021G>A) | 10 homozygotes | 4 (28.57%) | 23 (26.14%) | 0.8482 |
| 7 heterozygotes | ||||
| p.His1069Gln (c.3207A>G) | 12 homozygotes | 0 | 39 (44.32%) | 0.0015 |
| 15 heterozygotes | ||||
| Other variants | 1 homozygotes | 2 (14.29%) | 19 (21.59%) | 0.5304 |
| 19 heterozygotes | ||||
| Total alleles | 14 (100%) | 88 (100%) |
Table 3 Data regarding the patients evaluated for the HSD17B13:TA variant
| All | HSD17B13 genotype | |||
| T/T | TA/T | TA/TA | ||
| n (%) | 33 | 19 (57.58) | 12 (36.36) | 2 (6.06) |
| Females, n (%) | 16 | 11 | 5 | 0 |
| Mean age (yr) | 11.67 ± 3.12 | 11.09 ± 3.45 | 12.14 ± 2.25 | 14.70 ± 3.24 |
| Clinical presentation, n (%) | ||||
| ALF and/or hemolytic anemia | 7 (21.21) | 5 (71.43) | 2 (28.57) | 0 |
| Less severe hepatic forms | 26 (78.79) | 14 (53.85) | 10 (38.46) | 2 (7.69) |
| ATP7B variant | ||||
| p.His1069Gln (c.3206A>G)/p.His1069Gln (c.3206A>G) | 5 | 2 | 3 | 0 |
| p.His1069Gln (c.3206A>G)/p.Gly1341Asp (c.4021G>A) | 6 | 3 | 3 | 0 |
| p.His1069Gln (c.3206A>G)/other | 7 | 4 | 3 | 0 |
| p.Gly1341Asp (c.4021G>A)/p.Gly1341Asp (c.4021G>A) | 7 | 3 | 2 | 2 |
| p.Trp939Cys (c.2817G>T)/p.Trp939Cys (c.2817G>T) | 4 | 4 | 0 | 0 |
| p.Trp939Cys (c.2817G>T)/other | 1 | 1 | 0 | 0 |
| p.Lys844Ter (c.2530A>T)/p.Lys844Ter (c.2530A>T) | 1 | 1 | 0 | 0 |
| p.Lys844Ter (c.2530A>T)/ other | 2 | 1 | 1 | 0 |
- Citation: Pop TL, Grama A, Stefanescu AC, Willheim C, Ferenci P. Acute liver failure with hemolytic anemia in children with Wilson’s disease: Genotype-phenotype correlations? World J Hepatol 2021; 13(10): 1428-1438
- URL: https://www.wjgnet.com/1948-5182/full/v13/i10/1428.htm
- DOI: https://dx.doi.org/10.4254/wjh.v13.i10.1428
